findmyKOL
Clinical trialNCT04222413RecruitingPhase 1Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

SponsorNational Cancer Institute (NCI)Enrollment116Advanced Breast CancerAdvanced Solid TumorsColorectal NeoplasmsMalignant Peripheral Nerve Sheath TumorMetastatic Pancreatic CancerPediatric Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Kansas

    Fairway, Kansas, United States

    Recruiting
  • National Institutes of Health Clinical Center

    Bethesda, Maryland, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Oct 2020
Primary completion
31 Dec 2027
Completion
31 Dec 2028
Last update posted
8 Jul 2026
Registered enrollment
116
Registry id
NCT04222413
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.